Back to Search
JAMES BERENSON, M.D.
M.D.
Research Study Specialist
NPI: 1124051560IndividualAccepts Medicare
Specialties, Licenses & Credentials
Education
OTHER
Class of 1977
Research & Publications (20)
Hematology: Bortezomib in newly diagnosed multiple myeloma.
PMID 19390550·Nat Rev Clin Oncol·2009
8-other
A phase I study of samarium lexidronam/bortezomib combination therapy for the treatment of relapsed or refractory multiple myeloma.
PMID 19188182·Clin Cancer Res·2009
3-trial
Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss.
PMID 18829511·Clin Cancer Res·2008
3-trial
Comparison of twin and autologous transplants for multiple myeloma.
PMID 18804041·Biol Blood Marrow Transplant·2008
3-trial
Safety and efficacy of bortezomib and melphalan combination in patients with relapsed or refractory multiple myeloma: updated results of a phase 1/2 study after longer follow-up.
PMID 18463870·Ann Hematol·2008
3-trial
A phase I/II study of arsenic trioxide/bortezomib/ascorbic acid combination therapy for the treatment of relapsed or refractory multiple myeloma.
PMID 17363530·Clin Cancer Res·2007
3-trial
Arsenic compounds in the treatment of multiple myeloma: a new role for a historical remedy.
PMID 17229334·Clin Lymphoma Myeloma·2006
6-review
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 9201 W SUNSET BLVD, SUITE 310
WEST HOLLYWOOD, CA 90069 - Phone
- (310) 623-1222
Quick Facts
- NPI
- 1124051560
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 2
- Locations
- 1
- Years in Practice
- 49
- Publications
- 20
Are you this provider?
Claim Your Profile